Monika Hegi

20PUBLICATIONS
74CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Haematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 02, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

|Mar 05, 2025
Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.

Amélie Darlix, Pierre Bady, Jérémy Deverdun

|Jun 24, 2024
No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients.

Monika E Hegi, Felix B Oppong, James R Perry

|Jul 26, 2023
Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG.

Thi Tham Nguyen, Premnath Rajakannu, Minh Diêu Thanh Pham

|Jun 06, 2023
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.

Felix Sahm, Sebastian Brandner, Luca Bertero

|May 22, 2023
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation.

Vladimir Wischnewski, Roeltje R Maas, Paola Guerrero Aruffo

Pageof 4

Frequent Collaborators

5 joint publications

Wolfgang Wick

4 joint publications

Martin van den Bent

3 joint publications

Pierre Bady

3 joint publications

Johanna A Joyce